Preventing Arthritis in a Multi-Center Psoriasis At-Risk Cohort
Latest Information Update: 24 Jul 2024
At a glance
- Drugs Guselkumab (Primary) ; Antipsoriatics
- Indications Psoriasis; Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms PAMPA
- 15 Jun 2024 Results assessing the efficacy of the fully human interleukin (IL)-23p19-subunit inhibitor guselkumab in preventing PsA and reducing musculoskeletal ultrasound (US) abnormalities in a population of patients with psoriasis at increased risk of PsA progression, presented at the 25th Annual Congress of the European League Against Rheumatism.
- 04 Jan 2024 Planned End Date changed from 1 Sep 2025 to 1 Mar 2026.
- 04 Jan 2024 Planned primary completion date changed from 1 Mar 2025 to 31 Dec 2025.